Sihuan Pharmaceutical Holdings Group Ltd. announced that Insulin Aspart Injection, Insulin Aspart 30 Injection and Insulin Aspart 50 Injection developed by Huisheng Biopharmaceutical Co. Ltd. ("Huisheng Biopharmaceutical"), a non-wholly owned subsidiary of the Group, have obtained drug registration approval from the National Medical Products Administration (the " NMPA") of the People's Republic of China ("China") for the treatment of diabetes. As the first insulin product approved for marketing of Huisheng Biopharm pharmaceutical, it is a new milestone for Huisheng Biopharm Pharmaceutical to officially move from the research and development stage to the commercialization stage of its full range of products in the field of diabetes and complications.

Insulin Aspart Injection is the third-generation fast acting insulin analogue. It takes effect within 10-20 minutes after subcutaneous injection, which can better control postprandial blood glucose and reduce the risk of hypoglycemia. The injection time is more flexible and can be administered near mealtime, it can also be used for insulin pump and intravenous injection.

Insulin Aspart 30/50 Injections are biphasic insulins containing 30%/50% soluble insulin aspart and 70%/50% protamine insulin aspart. They can better control fasting and post-prandial blood glucose, reduce the number of injections, and has obvious advantages in improving patients' compliance and saving medical costs. The availability of two different dosages allows clinical physicians to provide patients with more flexible and personalized treatment options based on their postprandial blood glucose levels.

Insulin Aspart In injection, Insulin Aspart 30 in the National Reimbursement Drug List (2023 version) and classified in Category B. Diabetes is prevalent in China, where the number of diabetes patients ranks first in the world. According to the latest report of IDF, there was 140 million diabetes patients in China in 2021. As a chronic disease, diabetes patients require lifelong use of hypoglycemic drugs.

Insulin and its analogues play an important role in the treatment of diabetes, accounting for more than 50% of the market share in diabetes drugs, with huge demand. According to the annual report of Novo Nordisk, revenue of the three Insulin Aspart products in the Greater China reached RMB 5.9 billion in 2022.